Literature DB >> 26061072

Lymph Node Micrometastases in Early-Stage Cervical Cancer are Not Predictive of Survival.

Michael P Stany1, Pamela J B Stone, Juan C Felix, Charles A Amezcua, Susan Groshen, Wei Ye, Kathy L Kyser, Robin S Howard, Chris M Zahn, Laila I Muderspach, Scott E Lentz, Mildred R Chernofsky.   

Abstract

Although patients with early-stage cervical cancer have in general a favorable prognosis, 10% to 40% patients still recur depending on pathologic risk factors. The objective of this study was to evaluate if the presence of lymph node micrometastasis (LNmM) had an impact on patient's survival. We performed a multi-institutional retrospective review on patients with early-stage cervical cancer, with histologically negative lymph nodes, treated with radical hysterectomy and pelvic lymphadenectomy for the study period 1994 to 2004. Tissue blocks of lymph nodes from the patient's original surgery were recut and then evaluated for the presence of micrometastases. One hundred twenty-nine patients were identified who met inclusion criteria. LNmM were found in 26 patients (20%). In an average follow-up time of 70 mo, there were 11 recurrences (8.5%). Of the 11 recurrences, 2 (18%) patients had LNmM. Patients with LNmM were more likely to have received adjuvant radiation and chemotherapy. In stratified log-rank analysis, LNmM were not associated with any other high-risk clinical or pathologic variables. Survival data analysis did not demonstrate an association between the presence of LNmM and recurrence or overall survival. The presence of LNmM was not associated with an unfavorable prognosis nor was it associated with other high-risk clinical or pathologic variables predicting recurrence. Further study is warranted to understand the role of micrometastases in cervical cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26061072     DOI: 10.1097/PGP.0000000000000188

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  4 in total

1.  The Clinical Impact of Low-Volume Lymph Nodal Metastases in Early-Stage Cervical Cancer: The Senticol 1 and Senticol 2 Trials.

Authors:  Benedetta Guani; Vincent Balaya; Laurent Magaud; Fabrice Lecuru; Patrice Mathevet
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

Review 2.  [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes].

Authors:  Anne Kathrin Höhn; Christine E Brambs; Ramona Erber; Grit Gesine Ruth Hiller; Doris Mayr; Dietmar Schmidt; Elisa Schmoeckel; Lars-Christian Horn
Journal:  Pathologe       Date:  2021-05       Impact factor: 1.011

3.  Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study.

Authors:  Matteo Tantari; Stefano Bogliolo; Matteo Morotti; Vincent Balaya; Florent Bouttitie; Annie Buenerd; Laurent Magaud; Fabrice Lecuru; Benedetta Guani; Patrice Mathevet
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

4.  Risk Factor Assessment of Lymph Node Metastasis in Patients With FIGO Stage IB1 Cervical Cancer.

Authors:  Mu Xu; Xiaoyan Xie; Liangzhi Cai; Yongjin Xie; Qiao Gao; Pengming Sun
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.